[HTML][HTML] Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension …
HM Hoffman, ML Throne, NJ Amar, RC Cartwright… - Clinical …, 2012 - Elsevier
BACKGROUND: Cryopyrin-associated periodic syndromes (CAPS) are rare, inherited
autoinflammatory disorders associated with considerable hardship to patients. The
interleukin-1 inhibitor rilonacept has been shown to be well-tolerated and effective in
preventing CAPS symptoms in 2 pivotal studies. OBJECTIVE: In this study, the long-term
effects of rilonacept for improvement in CAPS symptoms and its safety and tolerability were
evaluated during extended treatment. METHODS: Patients with CAPS entered a 72-week …
autoinflammatory disorders associated with considerable hardship to patients. The
interleukin-1 inhibitor rilonacept has been shown to be well-tolerated and effective in
preventing CAPS symptoms in 2 pivotal studies. OBJECTIVE: In this study, the long-term
effects of rilonacept for improvement in CAPS symptoms and its safety and tolerability were
evaluated during extended treatment. METHODS: Patients with CAPS entered a 72-week …